戻る Agenda
Session 5: Integrated Adaptive Development and Decision Making
Session Chair(s)
Stella Blackburn, MD, MA, MSC, FFPM, FISPE, FRCP
Strategy
Consultant, United Kingdom
For patients with serious illnesses and unmet medical need, access to innovative medicines as early as possible is important. Randomised controlled clinical trials are important for establishing efficacy of a medicine but may provide only limited evidence of how a medicine will perform in the real world. There is relatively little known about the true safety profile of a drug at the time of “normal” authorisation and some critics voice concerns about patient safety as an argument against regulatory pathways providing earlier access. Some stakeholders are wanting evidence of effectiveness before making new medicines available for patients. How do we balance all these conflicting needs and how to we plan a development pathway to satisfy all, or at least most, stakeholders?
Speaker(s)
EMA Adaptive Pathways Pilot: What We’ve Learned and Future Direction
Hans-Georg Eichler, MD, MSC
Austrian Association of Social Security Bodies, Austria
Consulting Physician
Adaptive Biomedical Innovation: The Way Forward
Gigi Hirsch, MD
Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation, United States
Executive Director
Adapt Smart and Get Real: Where We Are and Where We Are Going
Sarah Garner, PHD
World Health Organization, Denmark
Acting Program Manager, Access to Medicines and Health Products